In recent years, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as sorafenib and regorafenib, have been approved for the first-line or second-line treatment of advanced HCC [2, 3]. Here, EGFR is linked to hepatocellular carcinoma.